Rheumnow Podcast
Abatacept Misses on Shingrix Response
Jun 15, 2024
Dr. David Liew discusses the suboptimal responses of rheumatoid arthritis patients on abatacept to the Shingrix vaccine at Eular 2024. The chapter highlights the importance of improving vaccination strategies for this group to enhance vaccine response.
02:08
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Abatacept treatment reduces Shingrix vaccine response over time.
- Adjusting vaccination protocols can enhance efficacy for patients on abatacept therapy.
Deep dives
Concerns about Shingrix Response in Rheumatoid Arthritis Patients on Abatacept
Rheumatoid arthritis patients undergoing Shingrix vaccination while on abatacept treatment displayed concerning results. The study revealed a modest increase in antibody response initially, with 64% responding at 12 weeks, which decreased to 21% by 60 weeks. The antibody titers were disappointing, and there was a significant lack of cellular response essential for combating herpes zoster. The findings suggest a need for better strategies to optimize vaccine responses in abatacept-treated patients, possibly by adjusting treatment protocols to enhance efficacy.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
